Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...

As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...

Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.

Atopic dermatitis in childhood is not associated with increased early markers of cardiovascular risk, a study finds.

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data ...

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced ...

Our highly trained dermatologists effectively diagnose and treat contact dermatitis in our clinic at University of Utah Health. Contact dermatitis is a skin disorder that occurs when a foreign ...

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today presented positive long-term ...

A common skin rash can be caused by fragrance, nickel, latex, even hair care products.

New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...